证券代码：000504 证券简称：南华生物 公告编号：2023-048 具体内容详见同日披露的《2023年半年度报告》及其摘要。 南华生物医药股份有限公司 第十一届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 南华生物医药股份有限公司（以下简称"公司"）第十一届监事会第十次会 议于2023年8月29日以通讯方式召开。会议通知于2023年8月21日以邮件、短信方 式送达公司全体监事。会议应参与表决监事3名，实际参与表决监事3名。会议召 开符合《公司法》及《公司章程》的有关规定，合法有效。 二、监事会议案审议情况 《关于<2023年半年度报告>及其摘要的议案》 经审核，公司监事会认为：董事会编制和审议《2023年半年度报告》及其摘 要的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整 地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：会议以3票赞成，0票反对，0票弃权，审议通过了《关于<2023年 半年度报告>及其摘要的议案》。 三、备查文件 经与会监事签字并 ...

南华生物医药股份有限公司独立董事 关于2023年半年度控股股东及其他关联方 2023 年 8 月 30 日 2.报告期内，公司不存在为控股股东及其他关联方、其他单位或个人提供违 规担保的情形。 南华生物医药股份有限公司独立董事 醋卫华 赵亚青 赵平 占用资金及对外担保情况的专项说明和独立意见 根据《中华人民共和国公司法》《上市公司独立董事规则》《深圳证券交易 所上市公司规范运作指引》等法律、法规和规范性文件，以及《公司章程》等的 相关规定，作为南华生物医药股份有限公司（以下简称"公司"）的独立董事， 基于独立判断的立场，对公司 2023 年上半年度公司控股股东及其他关联方占用 资金情况发表专项说明和独立意见，具体如下： 根据《关于规范上市公司与关联方资金往来及上市公司对外担保若干问题的 通知》《公司章程》等的相关规定，我们对 2023 年上半年度控股股东及其他关 联方占用资金情况及对外担保事项进行了核查。经核查，我们认为： 1.报告期内，公司不存在控股股东及其他关联方占用资金的情况，也不存在 将资金直接或间接提供给控股股东及其他关联方使用的情形； ...

法定代表人： 主管会计工作的负责人 ： 会计机构负责人： 2023年1-6月 | 编制单位：南华生物医药股份有限公司 | | | | | | | | | | 单位：人民币万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司核算的 会计科目 | 2023年期初 占用资金余额 | 2023年1-6月占 用累计发生金额 | 2023年1-6月占 用资金的利息 | 2023年1-6月偿还累 计发生金额 | 2023年6月30日 末 | 占用形成原因 | 占用性质 | | | | | | | （不含利息） | （如有） | | 占用资金余额 | | | | 控股股东、实际控制人及其附 | | | | | | | | | | 非经营性占用 | | 属企业 | | | | | | | | | | 非经营性占用 | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人及其 | | | | | | | ...

证券代码：000504 证券简称：南华生物 公告编号：2023-047 南华生物医药股份有限公司 第十一届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 南华生物医药股份有限公司（以下简称"公司"）第十一届董事会第十五次 会议于2023年8月29日以通讯方式召开。会议通知于2023年8月21日以邮件、短信 方式送达公司全体董事。会议应参与表决董事7名，实际参与表决董事7名。会议 召开符合《公司法》及《公司章程》等的有关规定，合法有效。 《关于<2023年半年度报告>及其摘要的议案》 公司《2023年半年度报告》及其摘要符合《证券法》及《深圳证券交易所股 票上市规则》及定期报告格式等的有关规定，能充分反映公司2023年上半年度的 实际经营情况。 表决结果：会议以7票赞成，0票反对，0票弃权，审议通过了《关于<2023年 半年度报告>及其摘要的议案》。 具体内容详见公司于同日披露的《2023年半年度报告》及其摘要。 三、备查文件 经与会董事签字并盖章的相关董事会决议。 特此公告。 南华生物医药股份有限公司董事会 ...

三、本批复自同意注册之日起 12个月内有效。 中国证券监督管理委员 证监许可〔2023〕1930 号 关于同意南华生物医药股份有限公司 中国证券监督管理委员会收到深圳证券交易所报送的关于你 公司向特定对象发行股票的审核意见及你公司注册申请文件。根 据《中华人民共和国证券法》《中华人民共和国公司法》《国务院 办公厅关于贯彻实施修订后的证券法有关工作的通知》(国办发 〔2020〕5 号 ）和《上市公司证券发行注册管理办法》( 证监会令 第 206号）等有关规定,经审阅深圳证券交易所审核意见及你公 司注册申请文件,现批复如下: 一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送深圳证券交易所的申报 文件和发行方案实施。 向特定对象发行股票注册的批复 南华生物医药股份有限公司: 四、自同意注册之日起至本次发行结束前,你公司如发生重 2023 8 24 ...

2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示: 1.本次股东大会未出现否决提案的情形； 2.本次股东大会未涉及变更以往股东大会已通过的决议。 证券代码：000504 证券简称：南华生物 公告编号：2023-046 南华生物医药股份有限公司 5.会议主持人：董事长杨云先生 6.会议召开的合法合规性：本次股东大会会议召开符合《公司法》《证券法》 《上市公司股东大会规则》等法律、法规和《公司章程》的规定。 1 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议召开时间：2023年8月25日下午15:00 （2）网络投票时间：2023年8月25日（星期五）。其中：通过深圳证券交易 所交易系统进行网络投票的具体时间为2023年8月25日9:15-9:25，9:30－11:30， 13:00-15:00；通过互联网投票系统进行网络投票的时间为2023年8月25日 9:15-15:00。 2.会议召开的地点：长沙高新开发区岳麓西大道1698号麓谷科技创新创业园 B1栋三层会议室 3.会议召开的 ...

地址：长沙市芙蓉区远大一路 280 号湘域相遇 B 座 4 楼、8 楼，C 座 4 楼 电话：（0731）84587101 84587102 传真：（0731）84587100 网址：http://www.xjlh.lawyer 湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2023 年第二次临时股东大会的 HUNAN XIANGJUNLUHE LAW FIRM 二○二三年八月 法律意见书 湖南湘军麓和律师事务所 湖南湘军麓和律师事务所 临时股东大会法律意见书 湖南湘军麓和律师事务所 关于南华生物医药股份有限公司 2023 年第二次临时股东大会的法律意见书 致：南华生物医药股份有限公司 （一）本次会议的召集 经查验，本次会议由公司第十一届董事会第十四次会议决定召开并由董事会 召集。公司董事会于 2023 年 8 月 8 日在《中国证券报》《证券时报》《证券日报》 湖南湘军麓和律师事务所 临时股东大会法律意见书 《上海证券报》和巨潮资讯网上公开公布了《关于召开 2023 年第二次临时股东 大会的通知》，该通知载明了本次会议现场会议召开的时间、方式、股权登记日、 出席对象及会议地点等事项；列明了提交本次会 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥34,739,572.68, a decrease of 46.40% compared to ¥64,818,635.90 in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥1,976,045.11, representing a decline of 1,335.77% from a profit of ¥159,904.25 in the previous year[5]. - Basic and diluted earnings per share were both -¥0.0063, a decrease of 1,360.00% from ¥0.0005 in the same period last year[5]. - Operating profit for the current period is -¥166,240.48, an improvement from -¥2,560,953.71 in the previous period[18]. - Net profit for the current period is ¥437,868.11, compared to a net loss of -¥3,237,533.29 in the previous period[18]. Cash Flow - The net cash flow from operating activities was ¥221,498.68, down 94.20% from ¥3,820,150.14 in the prior year[5]. - Cash flow from operating activities for the current period is ¥221,498.68, significantly lower than ¥3,820,150.14 in the previous period[20]. - Cash flow from investing activities shows a net outflow of -¥9,858,235.23, an improvement from -¥22,508,468.67 in the previous period[21]. - Cash flow from financing activities results in a net outflow of -¥3,440,558.04, compared to an inflow of ¥21,648,576.37 in the previous period[21]. - The ending cash and cash equivalents balance is ¥205,040,966.14, down from ¥155,964,954.55 in the previous period[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥554,426,832.54, an increase of 0.25% from ¥553,064,727.36 at the end of the previous year[5]. - The total liabilities increased slightly from 473,180,527.49 RMB to 474,104,764.56 RMB during the same period[15]. - The company's total equity as of March 31, 2023, was 80,322,067.98 RMB, up from 79,884,199.87 RMB at the beginning of the year[16]. - The cash and cash equivalents at the end of the reporting period were 205,070,966.14 RMB, compared to 218,148,260.73 RMB at the beginning of the year[13]. - The accounts receivable increased from 158,759,054.35 RMB to 168,247,960.76 RMB[13]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,088[10]. - The largest shareholder, Hunan Caixin Industrial Fund Management Co., Ltd., holds 25.58% of the shares, totaling 79,701,655 shares[10]. - The company has no preferred shareholders as of the reporting period[11]. Investment and Income - The company's investment income increased by 177.42% to ¥214,734.95 compared to a loss of ¥277,352.10 in the previous year[9]. - The company recorded a significant increase in non-operating income, totaling ¥1,000,000.00, up 761.12% from ¥116,127.27 in the previous year[9]. - The weighted average return on net assets was -15.46%, a decrease of 16.42% from 0.96% in the previous year[5]. - The company reported a 533.15% increase in trading financial assets, reaching ¥10,669,539.46, due to increased purchases of bank wealth management products[9]. Future Plans - The company plans to raise up to 276 million RMB through a private placement to supplement cash flow[12]. Audit Status - The first quarter report is not audited[22].

Financial Performance - The company's operating revenue for 2022 was ¥200,345,457.02, representing a 27.92% increase compared to ¥156,618,305.30 in 2021[22]. - The net profit attributable to shareholders of the listed company was -¥12,694,776.12, an improvement of 33.63% from -¥19,125,950.55 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥23,050,428.56, a decrease of 21.53% from -¥29,373,370.76 in 2021[22]. - Cash generated from operating activities increased by 55.35% to ¥166,381,243.04 from ¥107,098,005.73 in 2021[22]. - The total assets at the end of 2022 were CNY 553,064,727.36, a decrease of 16.11% from CNY 659,245,600.20 at the end of 2021[27]. - The net assets attributable to shareholders decreased by 17.24% to CNY 13,771,203.62 at the end of 2022 from CNY 16,640,394.08 at the end of 2021[27]. - The company reported a basic and diluted earnings per share of CNY -0.04 for 2022, improving from CNY -0.06 in 2021[27]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the past three years[27]. - The company reported a net profit of -¥29,761,420.25, indicating a significant discrepancy with the net cash flow from operating activities of ¥166,381,243.04, primarily due to growth in the cell storage business and improved collections from accounts receivable[81]. Business Strategy and Focus - The company has undergone a strategic adjustment in its major business focus from real estate and media to biomedicine and cell technology services since 2015[21]. - The company is focused on expanding its market presence in the biopharmaceutical sector, particularly in stem cell and immune cell storage services, leveraging its advanced technology and service quality[43]. - The company is actively involved in the development of new technologies in the biopharmaceutical field, including stem cell therapy and gene therapy, supported by national policies promoting innovation in healthcare[39]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[143]. - The company plans to strengthen its R&D capabilities by collaborating with research institutions and universities, focusing on stem cell and immune cell technologies[4]. Research and Development - The company has submitted nearly 30 intellectual property applications in the past three years, demonstrating a strong commitment to research and development in stem cell storage and clinical application technologies[44]. - The company has established a cell clinical application research system and built a cell flow culture room to enhance its capabilities in cell therapy and clinical transformation[44]. - R&D investment increased by 16.88% from ¥8,543,248.85 in 2021 to ¥9,985,226.68 in 2022, while the ratio of R&D investment to operating revenue decreased from 5.45% to 4.98%[74]. - The company is in the project initiation stage for a new hydrogel scaffold material for mesenchymal stem cell transplantation[71]. - The company aims to achieve clinical-grade autologous NK cell expansion, targeting the production of billions of NK cells from a single sample[72]. Market and Industry Trends - The energy-saving service industry in China has a total output value of 591.6 billion yuan, with a year-on-year growth of 13.3%, and is expected to reach 1 trillion yuan by 2025[37]. - The Chinese stem cell medical market was valued at 104.2 billion yuan in 2021, with projections indicating that the stem cell storage market will grow to 12.82 billion yuan by 2023, accounting for 9.41% of the total stem cell medical market[42]. - The company is positioned to benefit from the expanding market for cell therapy, which is expected to grow significantly in the coming years[35]. Governance and Management - The company maintains independent operations and governance, ensuring no interference from the controlling shareholder[117]. - The board of directors consists of 7 members, including 3 independent directors, adhering to governance regulations[118]. - The company has established a transparent information disclosure system, ensuring timely and accurate communication with investors[121]. - The company has a clear governance structure, with independent functioning of the shareholders' meeting, board of directors, and supervisory board[128]. - The company emphasizes the protection of stakeholder rights and maintains effective communication with investors[123]. Financial Management and Controls - The company has maintained effective internal controls over financial reporting as of December 31, 2022, with no significant deficiencies identified[177]. - The internal control self-assessment report indicated that all units included in the evaluation accounted for 100% of the company's total assets and revenue[175]. - The company reported a total audit fee of 61.35 million yuan for the fiscal year 2022, which includes 51.90 million yuan for financial audit services and 9.45 million yuan for internal control audit services[197]. - The company has not reported any significant changes in its financial performance or forecasts during the reporting period[192]. Employee and Talent Development - The total number of employees at the end of the reporting period was 512, with 287 in sales and 58 in production[166]. - The company plans to implement various training programs, including internal, external, and online training[169]. - The company has established a compensation policy that links income levels to company performance and departmental goals[170]. - The educational background of employees includes 7 with a doctorate, 33 with a master's degree, and 160 with a bachelor's degree[167]. Future Outlook - The company aims to enhance its operational efficiency and financial performance by optimizing its asset-liability structure and improving resource allocation[3]. - The company has set a performance guidance of 1.5 billion yuan in revenue for 2023, indicating a growth target of 25%[143]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficiency and user experience[147]. - The company plans to expand its market presence by entering three new provinces in 2023, aiming for a 15% increase in market share[143].

Financial Performance - The company's operating revenue for 2020 was ¥175,564,990.41, representing a 30.86% increase compared to ¥134,160,531.96 in 2019[18]. - The net profit attributable to shareholders of the listed company for 2020 was ¥8,154,550.92, a decrease of 56.64% from ¥18,806,368.87 in 2019[18]. - The overall net profit for the company was CNY 0.82 million, a decline of 56.64% year-on-year, primarily due to increased operational costs[43]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,654,615.66, an increase of 120.01% compared to the previous year[19]. - The net cash flow from operating activities was -¥207,220,871.68, a decrease of 1,526.91% year-on-year[19]. - The total assets at the end of 2020 were ¥556,140,141.52, representing a 107.26% increase from the end of 2019[19]. - The net assets attributable to shareholders increased by 44.28% to ¥26,568,530.39 compared to the end of 2019[19]. Business Operations - The company continues to focus on the biomedicine and cell technology services sector, which has been its main business since 2014[16]. - The revenue from the biopharmaceutical segment was ¥97,807,000, a decrease of 1.11% year-on-year, while the energy-saving and environmental protection segment revenue increased by 120.55% to ¥77,758,000[27]. - The company has established a clinical application research system for cell technology, enhancing its core competitiveness in cell storage services[30]. - The company received approval from the Hunan Provincial Health Commission to conduct stem cell and immune cell storage business in Hunan Province[31]. - The company has a professional technical team for stem cell and immune cell research, including Nobel Laureate Gregg L. Semenza, and has established strategic partnerships with renowned research institutions[32]. - The company has established a multi-level strategic cooperation mechanism with various hospitals for basic and clinical research, enhancing its market presence[35]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The actual controller of the company remains the Hunan Provincial People's Government after the share transfer[16]. - The company has maintained compliance with all commitments made to minority shareholders[110]. - The company guarantees that it will not engage in any business that competes with its main operations and will cease any such activities if they arise in the future[106]. - The company has not faced any delisting situations following the annual report disclosure[118]. - The company has established internal control mechanisms to prevent and detect material misstatements in financial reports[199]. Research and Development - The company initiated 6 independent R&D projects and 1 external research collaboration in 2020, focusing on stem cell and immune storage and detection[57]. - The number of R&D personnel increased by 50.00% from 92 in 2019 to 138 in 2020, accounting for 34.94% of the total workforce[63]. - R&D investment decreased by 67.93% from ¥15,515,677.43 in 2019 to ¥4,976,335.90 in 2020, representing only 2.83% of operating revenue[63]. Market and Industry Trends - The global stem cell market size was approximately $21.5 billion in 2010, exceeding $50 billion in 2014, and reaching $63.5 billion in 2015, with a compound annual growth rate of 24.2%[87]. - It is projected that the global stem cell market will reach $160 billion by 2021, indicating significant growth potential[87]. - In Hunan province, the stem cell storage rate is less than 1%, despite over 800,000 newborns annually, suggesting a vast market opportunity[87]. - The industry is experiencing increased competition, with foreign companies entering the market, posing challenges to domestic firms lacking core technologies and talent[94]. Financial Management - The company received financial support of ¥230 million from shareholders, contributing to a 46.99% increase in other payables[71]. - The company decided to extend a loan of 25.65 million yuan from Caixin Financial Holdings for one year at an interest rate of 4.35% per annum to supplement its liquidity[128]. - The company plans to borrow CNY 30 million from Hunan Caixin Financial Holdings Group for a period not exceeding 24 months at an interest rate of 4.75% per annum[130]. Audit and Compliance - The total audit fee for the current period was CNY 650,000, with CNY 550,000 allocated for the financial audit and internal control audit services[117]. - The internal control audit report was disclosed on March 31, 2021, and received a standard unqualified opinion[200]. - The company reported no significant internal control deficiencies during the reporting period[198]. Employee and Management Structure - The total number of employees is 395, with 384 from major subsidiaries and 11 from the parent company[176]. - The company adheres to a compensation policy linking income levels to company performance and long-term interests[178]. - The total remuneration for directors, supervisors, and senior management in the reporting period amounted to 2.8635 million yuan[173].